Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"

NetScientific is a transatlantic healthcare IP commercialisation group.
We fund and develop companies that significantly improve the health and well-being of people with chronic diseases.


Sector-specialist senior management team with extensive commercial experience.

  • Sir Richard Sykes, FRS

    Sir Richard Sykes, Non-Executive Chairman of the Group, joined NetScientific in 2008. Sir Richard spent thirty years working in the biotechnology and pharmaceutical industries, …

  • Francois Martelet, M.D.

    François Martelet, Chief Executive Officer, joined NetScientific Mid 2015. He brings over 20 years of biopharma experience and a proven track record of shaping and …

    Chief Executive Officer
  • Ian Postlethwaite

    Ian Postlethwaite, Chief Financial Officer, joined NetScientific in June 2016. He brings over 14 years of biopharma experience and a proven track record of …

    Chief Financial Officer & Company Secretary


22 March 2019 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF EU REGULATION 596/2014   NetScientific plc (“NetScientific” or the “Company”) Sale of …

19 March 2019 NetScientific plc (“NetScientific” or the “Company”) PDS merger with Edge Therapeutics update Further to its announcements on 26 November 2018 and 18 March 2019, …

Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer Growing product pipeline utilising Versamune®, a novel, versatile, multi-functional platform Phase …


NetScientific healthcare technology group